title: Tumor marker CA-125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle.
abstract: OBJECTIVE
  To further elucidate the origin of the physiological CA-125 amounts that lead to cyclic changes in CA-125 serum levels in normally menstruating women.
  
  
  METHODS
  Fifty-three normal endometria, 13 fallopian tubes, 25 ovaries, and nine isolated corpora lutea were prospectively investigated for their CA-125 content in a sandwich solid-phase RIA and by immunohistochemistry. In addition, endometrial CA-125 tissue content was compared with the actual CA-125 serum levels of the study patients.
  
  
  RESULTS
  Cytosolic CA-125 concentrations were 20-fold and twofold higher in the endometrium than those measured in the ovary and the fallopian tube, respectively. Moreover, only in the endometrium did CA-125 content show significant cyclic changes, with the highest concentrations during the early proliferative and middle secretory phase. The lowest tissue concentrations were measured during the early secretory phase. Furthermore, during the early and middle secretory phases cytosolic CA-125 was negatively associated with CA-125 serum levels. In immunohistochemistry, marked distributional changes in OC-125 reactivity were revealed in the basalis and the functionalis throughout the menstrual cycle and the postovulatory loss of CA-125 expression was found to be strongly connected with early secretory transformation of glandular epithelium.
  
  
  CONCLUSIONS
  Our findings indicate that the CA-125 amounts responsible for cyclic changes in serum levels in normally menstruating women seem to be a product of normal endometrium.
authors: Department of Obstetrics and Gynecology, Innsbruck University Clinic, Austria.
authors: A G
authors: AG
authors: Zeimet
authors: E
authors: E
authors: Müller-Holzner
authors: C
authors: C
authors: Marth
authors: G
authors: G
authors: Daxenbichler
authors: O
authors: O
authors: Dapunt
mesh_terms: D000328:Adult; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis* / Q000097:blood*; D002278:Carcinoma in Situ / Q000473:pathology / Q000601:surgery; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000601:surgery; D004717:Endometrium / Q000473:pathology; D005187:Fallopian Tubes / Q000473:pathology; D005260:Female; D005836:Genitalia, Female / Q000166:cytology / Q000473:pathology*; D006801:Humans; D007044:Hysterectomy; D007150:Immunohistochemistry; D008597:Menstrual Cycle / Q000097:blood*; D010053:Ovary / Q000473:pathology; D002578:Uterine Cervical Dysplasia / Q000473:pathology / Q000601:surgery; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000601:surgery
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate